Afimkibart  (Synonyms: PF-06480605; RVT-3101)

Afimkibart (PF-06480605; RVT-3101) is a fully human monoclonal antibody that selectively inhibits trimeric tumor necrosis factor-like ligand 1A (TL1A). Afimkibart neutralizes active trimeric TL1A, blocks TL1A-induced signaling pathways. Afimkibart inhibits NF-κB activation and IFN-γ production. Afimkibart can be used for the research of inflammatory bowel disease^[1].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

Afimkibart selectively binds to functionally active trimeric recombinant human TL1A and does not bind to monomeric recombinant human TL1A^[1].
Afimkibart potently inhibits trimeric recombinant human TL1A-induced NF-κB activation in human peripheral T lymphocytes and trimeric recombinant human TL1A/IL12/IL18-induced IFN-γ production in human PBMCs^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

9966  [NCBI]

O95150

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

146.54 kDa

2911580-96-4

Liquid

Colorless to light yellow

[Afimkibart]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  IgG1-kappa

• 
  Immobilized TL1A/TNFSF15 Trimer Protein, Human can bind Afimkibart. The EC₅₀ for this effect is 8.563 ng/mL.
• 
  Flow cytometric analysis of 1.5X10⁶ HT-29 cells with Afimkibart (HY-P990876, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa, Isotype Control (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

• [1]. Fuh F, et al. P0011Functional Advantage of Afimkibart’s Preference for Trimeric TL1A in Blocking Active TL1A Signaling[J]. Journal of Crohn’s and Colitis, 2026, 20(Supplement_1): jjaf231. 192.